Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Trastuzumab Emtansine”

117 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 117 results

Early research (Phase 1)Study completedNCT01513083
What this trial is testing

Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function

Who this might be right for
Breast Cancer
Hoffmann-La Roche 28
Testing effectiveness (Phase 2)Looking for participantsNCT05673928
What this trial is testing

A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)

Who this might be right for
Metastatic Solid TumorBrain Metastases
M.D. Anderson Cancer Center 30
Early research (Phase 1)Study completedNCT00928330
What this trial is testing

Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy

Who this might be right for
Metastatic Breast Cancer
Genentech, Inc. 57
Not applicableActive Not RecruitingNCT05889988
What this trial is testing

Ado-trastuzumab Emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients

Who this might be right for
Breast Neoplasm
Mayo Clinic 36
Large-scale testing (Phase 3)Study completedNCT01419197
What this trial is testing

Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy

Who this might be right for
Breast Cancer
Hoffmann-La Roche 602
Large-scale testing (Phase 3)Active Not RecruitingNCT03975647
What this trial is testing

Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Seagen, a wholly owned subsidiary of Pfizer 466
Early research (Phase 1)Study completedNCT03364348
What this trial is testing

4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer

Who this might be right for
HER2 Positive Breast CarcinomaRecurrent Breast CarcinomaStage III Breast Cancer+4 more
George W. Sledge Jr. 18
Testing effectiveness (Phase 2)Active Not RecruitingNCT03587740
What this trial is testing

ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer

Who this might be right for
Breast Cancer
Dana-Farber Cancer Institute 111
Early research (Phase 1)Study completedNCT04509596
What this trial is testing

DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer

Who this might be right for
Breast Cancer Metastatic
Dizal Pharmaceuticals 23
Testing effectiveness (Phase 2)Ended earlyNCT03190967
What this trial is testing

T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery

Who this might be right for
Breast CancerBrain MetastasisBrain Cancer
National Cancer Institute (NCI) 12
Testing effectiveness (Phase 2)Study completedNCT02999672
What this trial is testing

Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors

Who this might be right for
Bladder CancerPancreas CancerCholangiocellular Carcinoma
Hoffmann-La Roche 20
Testing effectiveness (Phase 2)UnknownNCT03225937
What this trial is testing

Evaluation of Trastuzumab in Combination With Lapatinib or Pertuzumab in Combination With Trastuzumab-Emtansine to Treat Patients With HER2-positive Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Fondazione del Piemonte per l'Oncologia 54
Not applicableUnknownNCT05754502
What this trial is testing

Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy

Who this might be right for
Breast Cancer
Consorzio Oncotech 300
Large-scale testing (Phase 3)Looking for participantsNCT07673029
What this trial is testing

A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
GeneQuantum Healthcare (Suzhou) Co., Ltd. 228
Early research (Phase 1)Study completedNCT00932373
What this trial is testing

Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen

Who this might be right for
Metastatic Breast Cancer
Genentech, Inc. 54
Testing effectiveness (Phase 2)Study completedNCT02657343
What this trial is testing

An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.

Who this might be right for
Breast Cancer
Dana-Farber Cancer Institute 25
Not applicableUnknownNCT05560308
What this trial is testing

Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI Therapy

Who this might be right for
HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy
Tianjin Medical University Cancer Institute and Hospital 50
Not applicableLooking for participantsNCT06272799
What this trial is testing

Tolerability and Efficacy of Adjuvant T-DM1 in Patients with HER2 Positive Breast Cancer After Incomplete Pathological Response to Neoadjuvant Chemotherapy Including Anti-HER2 Agents.

Who this might be right for
Breast Cancer
Regina Elena Cancer Institute 160
Testing effectiveness (Phase 2)Study completedNCT01597414
What this trial is testing

Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1

Who this might be right for
Elderly Metastatic Breast Cancer Population
European Organisation for Research and Treatment of Cancer - EORTC 80
Early research (Phase 1)Study completedNCT02073916
What this trial is testing

T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Jenny C. Chang, MD 24
Next Page